NANO-PHOTOMED

Targeted Nano-Photomedicines for Multi-spectral Photodynamic Therapy of Cancer

 Coordinatore AMRITA VISHWA VIDYAPEETHAM 

 Organization address address: ETTIMADAI
city: COIMBATORE
postcode: 641105

contact info
Nome: Shanti
Cognome: Nair
Email: send email
Telefono: -
Fax: -

 Nazionalità Coordinatore India [IN]
 Totale costo 15˙000 €
 EC contributo 15˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2007-4-2-IIF
 Funding Scheme MC-IIFR
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-10-01   -   2010-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    AMRITA VISHWA VIDYAPEETHAM

 Organization address address: ETTIMADAI
city: COIMBATORE
postcode: 641105

contact info
Nome: Shanti
Cognome: Nair
Email: send email
Telefono: -
Fax: -

IN (COIMBATORE) coordinator 15˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

deep    drugs    cell    mri    dose    micro    ps    specifically    photomedicines    photosensitizer    treatment    spectral    molecular    tumor    nano    ligands    imaging    tissue    radiations    vasculature    photodynamic    conjugated    agents    nanomedicine    qd    photo   

 Obiettivo del progetto (Objective)

'We propose to develop multifunctional, targeted nano-photomedicines that are capable of bypassing biological barriers to deliver nano-engineered photosensitizer drugs and molecular-imaging agents to tumor tissues and angiogenetic micro-vasculature. Specifically, a unique nanomedicine system for targeted multi-spectral photodynamic therapy is proposed. The system consists of (i) luminescent quantumdot (QD) conjugated with photosensitizer (PS) drugs, which can be sensitized at its maximum efficiency using radiations of deep-tissue penetration (ii) molecular-imaging agents for the early stage detection and in situ treatment-effect analysis (iii) active targeting ligands to specifically target tumor and micro-vasculature. During the incoming phase, QDs of ZnS, Y2O3 and Gd2O3 emitting multi-spectral light under excitation with deep high-tissue penetrating radiations will be conjugated with PS so as to sensitize them at their characteristic absorption using Fluorescent Resonant Energy Transfer (FRET). The QD-PS will be combined with MRI contrast agents using `core/shell’ nanotechnology and made water soluble by capping with polyethylene glycol (PEG). Finally, the nanomedicine will be connected with tumor specific ligands such as folic acid, MAbs and peptides. Optimization of nanomedicine will be carried out by studying dark and photo-toxicity in normal and cancer cell-lines in vitro. Photodynamic treatment will be carried out in pre-clinical animal models using multispectral radiations under different photo- and drug-dose conditions, followed by molecular imaging (MRI) based estimation of PDT response-dose inter-relationships. During the return phase, scanning probe imaging based investigations on the mechanism-of-activity of nano-photomedicines at intra-cellular regions leading to cell-death (apoptosis) will be investigated.'

Altri progetti dello stesso programma (FP7-PEOPLE)

MULTISELF (2014)

Multiple levels of selection in Fungi

Read More  

LIBEAC (2013)

Liberalism in Between Europe and China

Read More  

ESYMBIOSIS (2014)

Molecular Basis of Coral Symbiosis

Read More